Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Targeted therapy and immunotherapy have transformed advanced non-small cell lung cancer (NSCLC) treatment.
• These innovative therapies are increasingly being explored in the adjuvant setting for early-stage NSCLC.
• Approved adjuvant treatments include osimertinib for EGFR-mutated NSCLC and atezolizumab/pembrolizumab for resectable NSCLC.

Purpose of the Study:

• To review recent advancements in adjuvant targeted therapy and immunotherapy for early-stage non-small cell lung cancer (NSCLC).
• To summarize ongoing clinical trials investigating these treatment modalities in the adjuvant setting.
• To address unresolved questions regarding optimal adjuvant treatment strategies for early-stage NSCLC.

Main Methods:

• Literature review of available studies on adjuvant targeted therapy and immunotherapy for early-stage NSCLC.
• Focus on recent clinical trial data and approved adjuvant treatments.
• Synthesis of current evidence and identification of ongoing research.

Main Results:

• Several targeted therapies and immunotherapies are being investigated in the adjuvant setting for early-stage NSCLC.
• Osimertinib, atezolizumab, and pembrolizumab are among the approved or studied adjuvant options.
• Numerous clinical trials are underway to further evaluate efficacy and optimal use.

Conclusions:

• Adjuvant targeted therapy and immunotherapy represent a rapidly evolving field in early-stage NSCLC management.
• Ongoing research aims to define the optimal strategies and patient populations for these treatments.
• Further investigation is crucial to answer remaining questions and refine adjuvant treatment protocols for NSCLC.